WO2000065028A3 - TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR - Google Patents

TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR Download PDF

Info

Publication number
WO2000065028A3
WO2000065028A3 PCT/US2000/011564 US0011564W WO0065028A3 WO 2000065028 A3 WO2000065028 A3 WO 2000065028A3 US 0011564 W US0011564 W US 0011564W WO 0065028 A3 WO0065028 A3 WO 0065028A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
methods
peptides
polypeptides
functional fragments
Prior art date
Application number
PCT/US2000/011564
Other languages
French (fr)
Other versions
WO2000065028A9 (en
WO2000065028A2 (en
Inventor
Daniel R Twardzik
Stefan Paskell
Thomas S Felker
Original Assignee
Stem Cell Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/299,473 external-priority patent/US20020099008A1/en
Application filed by Stem Cell Pharmaceuticals Inc filed Critical Stem Cell Pharmaceuticals Inc
Priority to AU46793/00A priority Critical patent/AU4679300A/en
Priority to DE60035192T priority patent/DE60035192T2/en
Priority to EP00928576A priority patent/EP1176870B1/en
Priority to CA002371241A priority patent/CA2371241A1/en
Priority to JP2000614365A priority patent/JP2002543096A/en
Publication of WO2000065028A2 publication Critical patent/WO2000065028A2/en
Publication of WO2000065028A3 publication Critical patent/WO2000065028A3/en
Publication of WO2000065028A9 publication Critical patent/WO2000065028A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Disclosed are peptides related to human TGF-α, having TGF-α biological activity, which are useful for many of the indications that full-length TGF-α polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF-α and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF-α related peptides to related neurode generative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.
PCT/US2000/011564 1999-04-26 2000-04-26 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR WO2000065028A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU46793/00A AU4679300A (en) 1999-04-26 2000-04-26 Tgf-alpha polypeptides, functional fragments and methods of use therefor
DE60035192T DE60035192T2 (en) 1999-04-26 2000-04-26 TGF-ALPHA POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHOD FOR THEIR USE
EP00928576A EP1176870B1 (en) 1999-04-26 2000-04-26 Tgf-alpha polypeptides, functional fragments and methods of use therefor
CA002371241A CA2371241A1 (en) 1999-04-26 2000-04-26 Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
JP2000614365A JP2002543096A (en) 1999-04-26 2000-04-26 TGF-α polypeptides, functional fragments and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/299,473 US20020099008A1 (en) 1999-04-26 1999-04-26 Method for stimulating hematopoiesis using tgf-alpha
US09/299,473 1999-04-26
US09/459,813 1999-12-13
US09/459,813 US6764683B1 (en) 1999-04-26 1999-12-13 Loop peptide and TGFα for stimulating stem cell proliferation and migration

Publications (3)

Publication Number Publication Date
WO2000065028A2 WO2000065028A2 (en) 2000-11-02
WO2000065028A3 true WO2000065028A3 (en) 2001-05-03
WO2000065028A9 WO2000065028A9 (en) 2002-03-14

Family

ID=26971235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011564 WO2000065028A2 (en) 1999-04-26 2000-04-26 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR

Country Status (8)

Country Link
US (4) US6486122B1 (en)
EP (1) EP1176870B1 (en)
JP (1) JP2002543096A (en)
AT (1) ATE364315T1 (en)
AU (1) AU4679300A (en)
CA (1) CA2371241A1 (en)
DE (1) DE60035192T2 (en)
WO (1) WO2000065028A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795202B2 (en) * 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US20010007657A1 (en) * 1997-08-04 2001-07-12 Reid James Steven Compositions and methods for manipulating glial progenitor cells and treating neurological deficits
AU743251B2 (en) * 1997-08-04 2002-01-24 Regents Of The University Of California, The Methods for treating neurological deficits
CA2372119A1 (en) * 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
JP2003522131A (en) * 1999-08-19 2003-07-22 ステム セル ファーマシューティカルズ，インコーポレーテッド TGF-α polypeptides, functional fragments and uses thereof
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
WO2006128125A2 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US20070031373A1 (en) * 2005-08-04 2007-02-08 Carlos Lopez Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors
TW201500549A (en) 2013-06-19 2015-01-01 Univ Taipei Medical Method and device for enhancing a directional migration of stem cells
US20170305986A1 (en) * 2014-10-10 2017-10-26 Neurorepair, Inc. Novel tgf-alpha mutant proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001141A1 (en) * 1989-07-13 1991-02-07 The Rockefeller University MODIFIED TRANSFORMING GROWTH FACTOR α OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
JPS6034997A (en) 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ Biologically active polypeptides
US4863899A (en) 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
ATE85080T1 (en) 1984-02-17 1993-02-15 Genentech Inc HUMAN TRANSFORMATIONAL GROWTH FACTOR AND PRECURSORS OR FRAGMENTS THEREOF, CELLS, DNA, VECTORS AND METHODS FOR THEIR PRODUCTION, COMPOSITIONS AND PRODUCTS CONTAINING THEM, AND ANTIBODIES AND DIAGNOSTIC METHODS DERIVED THEREOF.
US4749683A (en) 1985-01-25 1988-06-07 President And Fellows Of Harvard College Inhibition of gastric acid secretion with alpha-transforming growth factor
AU5249786A (en) * 1985-01-29 1986-08-07 Oncogen Wound healing compositions
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DK354487A (en) * 1986-07-11 1988-01-12 Noboru Yanaihara ONCOGEN-RELATED PEPTIDES
US4874746A (en) 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5102870A (en) * 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
JPH04352800A (en) 1990-10-26 1992-12-07 Childrens Medical Center Corp:The Smooth muscle mitogen
US5229493A (en) 1990-10-26 1993-07-20 Children's Medical Center Corporation Smooth muscle mitogen
US5886141A (en) 1990-10-26 1999-03-23 Takeda Chemical Industries, Ltd. Smooth muscle mitogen peptides and DNA coding therefor
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
JPH06509563A (en) * 1991-07-05 1994-10-27 セラゲン・インコーポレイテッド Molecules targeting epidermal growth factor receptors for the treatment of inflammatory arthritis
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
US5885956A (en) 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
DE69433661T2 (en) 1993-01-29 2005-02-10 Neurospheres Holding Ltd., Calgary GENETIC MODIFICATION OF NEURAL STEM CELLS
GB9500660D0 (en) * 1995-01-13 1995-03-08 Secr Defence Growth factor anologs
US5840687A (en) * 1995-02-02 1998-11-24 Schering Aktiengesellschaft Modified ligands for receptor tyrosine kinases
ATE231727T1 (en) 1995-11-09 2003-02-15 Takeda Chemical Industries Ltd COMPOSITION FOR IMPROVEMENT OF PANCREAS FUNCTION
WO1997025349A1 (en) 1996-01-04 1997-07-17 Human Genome Sciences, Inc. Transforming growth factor alpha hiii
US5814308A (en) 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
EP0941109A1 (en) 1996-11-15 1999-09-15 Neurospheres Holdings Ltd. Pretreatment with growth factors to protect against cns damage
JPH10158188A (en) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
WO1998024468A1 (en) 1996-12-04 1998-06-11 Clark Abbot F TGFα FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
AU5530198A (en) 1996-12-16 1998-07-15 Zymogenetics Inc. Compositions and methods for stimulating pancreatic islet cell regeneration
AU743251B2 (en) * 1997-08-04 2002-01-24 Regents Of The University Of California, The Methods for treating neurological deficits
EP1175487A2 (en) 1999-02-10 2002-01-30 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6037357A (en) * 1999-04-21 2000-03-14 Unitech Pharmaceuticals, Inc. N-benzoyl-α-alkylated azatyrosines as anticancer agents
JP2003522131A (en) * 1999-08-19 2003-07-22 ステム セル ファーマシューティカルズ，インコーポレーテッド TGF-α polypeptides, functional fragments and uses thereof
US20020193301A1 (en) * 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
AU2001294647A1 (en) * 2000-09-22 2002-04-02 Stem Cell Pharmaceuticals, Inc. Method or treatment of tumors using transforming growth factor-alpha

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001141A1 (en) * 1989-07-13 1991-02-07 The Rockefeller University MODIFIED TRANSFORMING GROWTH FACTOR α OLIGOPEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1

Also Published As

Publication number Publication date
ATE364315T1 (en) 2007-07-15
EP1176870B1 (en) 2007-06-13
WO2000065028A9 (en) 2002-03-14
JP2002543096A (en) 2002-12-17
US7365172B2 (en) 2008-04-29
US6486122B1 (en) 2002-11-26
US20020169131A1 (en) 2002-11-14
AU4679300A (en) 2000-11-10
DE60035192D1 (en) 2007-07-26
CA2371241A1 (en) 2000-11-02
DE60035192T2 (en) 2008-02-14
WO2000065028A2 (en) 2000-11-02
US20060105957A1 (en) 2006-05-18
EP1176870A4 (en) 2002-07-31
EP1176870A2 (en) 2002-02-06
US20090068139A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
PT698108E (en) ADENOVATIVE VECTORS OF ANIMAL ORIGIN AND USES IN GENE THERAPY
EP1196444B8 (en) Exendin-4 conjugates and their medical use
BR9907259A (en) Compounds for therapy and diagnosis of lung cancer and processes for their use
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
HK1160392A1 (en) Determination of the prognosis of a patient undergoing treatment for alzheimer's disease
WO2001011048A3 (en) Therapeutic polypeptides and methods for using same
CA2257133A1 (en) Human dnase i hyperactive variants
GR3035440T3 (en) Therapeutic uses of bpi protein products for human meningococcemia
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
BR9808509A (en) Compositions and methods for the treatment and diagnosis of breast cancer
HUT78092A (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
DE69835680D1 (en) THERAPEUTIC USE OF SMR1 PROTEIN AND ITS ACTIVE DERIVATIVES
MXPA05008704A (en) Fusion proteins of interferon alpha muteins with improved properties.
EP1281763A3 (en) Early growth response-1 (EGR-1) transcription factor
HU902004D0 (en) New trombolitic preparations
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
EP0967276A3 (en) Anti-tumor agent comprising salmosin
YU60199A (en) New bpc peptide salts with organo-protective activity,the process for their preparation and their use in therapy
AU6819898A (en) Oxygen anion radicals and/or therapeutic preparations containing their reaction or breakdown products, and use of such preparations in the treatment of parkinson's disease
WO1999050289A3 (en) Transformation progression-related genes and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2371241

Country of ref document: CA

Ref country code: CA

Ref document number: 2371241

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 614365

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 46793/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000928576

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928576

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWG Wipo information: grant in national office

Ref document number: 2000928576

Country of ref document: EP